IASON acquired by Curium
Curium acquired IASON in June of 2021, further expanding its footprint in Europe for its
Together with medicine, IASONÂ serves the patient with competence
The core competences of IASON include the distribution of pharmaceuticals with a very short shelf-life, as well as the implementation of safety tools for radioactivity and of the most modern hygienic standards for the handling of pharmaceuticals.
Technology
A cyclotron is at the heart of the complex production process for our PET radiopharmaceuticals. In addition, IASON develops and manufactures lab kits and specialised products for the target groups nuclear medicine and laboratory medicine and supplies them to customers worldwide.
Research
IASON is one of the most innovative companies in the field. Therefore, Research & Development plays a key role in maintaining this leading position. One major objective set by IASON’s management is to bring a new PET radiopharmaceutical to Marketing Authorization every two years.
Consulting
Drawing on years of experience in this highly complex field, IASON disposes of profound competency and expert knowledge in the operation of cyclotron based production plants for the manufacture of radiopharmaceuticals.
